Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 28

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 28
---
 in accordance with our procedures detailed in the section below entitled “Stockholder Proposals.” Board Diversity The following table presents our board diversity statistics, as self-disclosed by our directors.

| Board Diversity (As of April 14, 2025) |   |        |   |     |      |
|:---------------------------------------|--:|:-------|--:|:----|-----:|
| Total Number of Directors              | 8 |        |   |     |      |
|                                        |   | Female |   |     | Male |
| Part I: Gender Identity                |   |        |   |     |      |
| Directors                              |   |        | 3 |     |    5 |
| Part II: Demographic Background        |   |        |   |     |      |
| White                                  |   |        | 3 |     |    4 |
| Hispanic                               |   |        | — |     |    1 |
| LGBTQ+                                 | 1 |        |   |     |      |

<div align='center'>17</div>

Director Attendance at Annual Meetings

We do not have a formal policy regarding attendance by members of our board of directors at our annual meeting. Six of our directors attended our annual meeting of stockholders in 2024.

Communications with our Board of Directors

Stockholders seeking to communicate with our board of directors should submit their written comments to our corporate secretary, Crinetics Pharmaceuticals, Inc., 6055 Lusk Boulevard, San Diego, CA 92121, Attention: Corporate Secretary. The corporate secretary will forward such communications to each member of our board of directors; provided that, if in the opinion of our corporate secretary it would be inappropriate to send a particular stockholder communication to a specific director, such communication will only be sent to the remaining directors (subject to the remaining directors concurring with such opinion).

Insider Trading Compliance Policy

Wemaintain an Insider Trading Compliance Policy, which governs the purchase, sale or other disposition of Company securities by directors, officers and employees that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and the listing standards of Nasdaq. Our directors, officers and employees are subject to certain “blackout periods,” and certain directors, officers and employees are subject to preclearance requirements prior to effecting any transaction involving our securities, except for trades made pursuant to a pre-approved Rule 10b5-1 trading plan. A copy of our Insider Trading Compliance Policy was filed